Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

REGISTER for free or LOG IN to view this content

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Structural Heart

TCT 2021

Mitral Valve

Up Next

Presentation TCT 2021

Pro: Is Impella CP the First-line MCS of Choice for Acute MI and Cardiogenic Shock?

Presenter: A. Reshad Garan

November 05, 2021

More slides +

Presentation TCT 2021

Con: Is Impella CP the First-line MCS of Choice for Acute MI and Cardiogenic Shock?

Presenter: Sandeep Nathan

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.